Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

G. Saggu; D. Stroopinsky; A. Z. Dudek; A. J. Olszanski; D. Juric; A. Dowlati; U. Vaishampayan; H. Assad; J. Rodón; J. Gibbs; J. Green; Z. Du; R. Rudicell; K. Kannan; R. Gharavi; A. Gomez-Pinillos; R. J. Fram; A. Berger; K. Sachsenmeier; S. Kasar

doi:10.1016/S0959-8049(22)01134-0

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

G. Saggu, D. Stroopinsky, A. Z. Dudek, A. J. Olszanski, D. Juric, A. Dowlati, U. Vaishampayan, H. Assad, J. Rodón, J. Gibbs, J. Green, Z. Du, R. Rudicell, K. Kannan, R. Gharavi, A. Gomez-Pinillos, R. J. Fram, A. Berger, K. Sachsenmeier, S. Kasar

Investigational Cancer Therapeutics

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	S125-S126
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)01134-0
State	Published - Oct 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(22)01134-0

Cite this

Saggu, G., Stroopinsky, D., Dudek, A. Z., Olszanski, A. J., Juric, D., Dowlati, A., Vaishampayan, U., Assad, H., Rodón, J., Gibbs, J., Green, J., Du, Z., Rudicell, R., Kannan, K., Gharavi, R., Gomez-Pinillos, A., Fram, R. J., Berger, A., Sachsenmeier, K., & Kasar, S. (2022). Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study. European Journal of Cancer, 174, S125-S126. https://doi.org/10.1016/S0959-8049(22)01134-0

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study. / Saggu, G.; Stroopinsky, D.; Dudek, A. Z. et al.
In: European Journal of Cancer, Vol. 174, 10.2022, p. S125-S126.

Research output: Contribution to journal › Article › peer-review

Saggu, G, Stroopinsky, D, Dudek, AZ, Olszanski, AJ, Juric, D, Dowlati, A, Vaishampayan, U, Assad, H, Rodón, J, Gibbs, J, Green, J, Du, Z, Rudicell, R, Kannan, K, Gharavi, R, Gomez-Pinillos, A, Fram, RJ, Berger, A, Sachsenmeier, K & Kasar, S 2022, 'Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study', European Journal of Cancer, vol. 174, pp. S125-S126. https://doi.org/10.1016/S0959-8049(22)01134-0

Saggu G, Stroopinsky D, Dudek AZ, Olszanski AJ, Juric D, Dowlati A et al. Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study. European Journal of Cancer. 2022 Oct;174:S125-S126. doi: 10.1016/S0959-8049(22)01134-0

Saggu, G. ; Stroopinsky, D. ; Dudek, A. Z. et al. / Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study. In: European Journal of Cancer. 2022 ; Vol. 174. pp. S125-S126.

@article{846891bf45504d1580e1750f813305aa,

title = "Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study",

author = "G. Saggu and D. Stroopinsky and Dudek, {A. Z.} and Olszanski, {A. J.} and D. Juric and A. Dowlati and U. Vaishampayan and H. Assad and J. Rod{\'o}n and J. Gibbs and J. Green and Z. Du and R. Rudicell and K. Kannan and R. Gharavi and A. Gomez-Pinillos and Fram, {R. J.} and A. Berger and K. Sachsenmeier and S. Kasar",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)01134-0",

language = "English (US)",

volume = "174",

pages = "S125--S126",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

AU - Saggu, G.

AU - Stroopinsky, D.

AU - Dudek, A. Z.

AU - Olszanski, A. J.

AU - Juric, D.

AU - Dowlati, A.

AU - Vaishampayan, U.

AU - Assad, H.

AU - Rodón, J.

AU - Gibbs, J.

AU - Green, J.

AU - Du, Z.

AU - Rudicell, R.

AU - Kannan, K.

AU - Gharavi, R.

AU - Gomez-Pinillos, A.

AU - Fram, R. J.

AU - Berger, A.

AU - Sachsenmeier, K.

AU - Kasar, S.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140445601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140445601&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)01134-0

DO - 10.1016/S0959-8049(22)01134-0

M3 - Article

AN - SCOPUS:85140445601

SN - 0959-8049

VL - 174

SP - S125-S126

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this